Release time: 2022/12/22 09:00
Last updated: 2022/12/22 09:33
With more than 20 years of biomedical and health care experience and professional R&D background, Translab International Ltd. General Manager Huang Mingxin (left) and Translab International Ltd. Vice General Manager Yang Zhonghan, co-founder and former secretary-general of the Taiwan Fucoidan Development Association, work together and made significant progress in the research of oligo fucoidan in Taiwan.
In the past, most people who used fucoidan aimed for the benefits & effects of basic modulation, appetite, physical strength and physical enhancement. However, the extraction technology applied in Taiwan’s small molecule fucoidan for the health food has long had problems such as poor water solubility and purity. These problems were finally solved by Translab’s FOII® patented extraction technology, the FOII® second-generation oligo fucoidan. Its physiological activity has been confirmed through human clinical trials. This research result is through the join collaboration of Taiwan’s industry, government, medical, academia, and research sectors.
With more than 20 years of experience in the field of crude drug development and academic research, Translab International Ltd. General Manager Huang Mingxin and Deputy General Manager Yang Zhonghan led a professional R&D team to cooperate with various medical research units through “translational medicine” research to develop the patented FOII ® second-generation oligo fucoidan, recent scientific research results have been published in international medical journals and human clinical trials have achieved outstanding results, setting off major changes in Taiwan’s biotechnology research and development.
Translab joins hands with international authorities to successfully upgrade small molecule oligo fucoidan extraction technology
Taiwan’s small molecule oligo fucoidan has been developed for many years and has benefited many patients facing critical health problems. It has been recognized by nearly 60 international journals and clinical trials. Its functions and mechanisms have even been listed in the Dictionary of Natural Objects, NCI at the National Institutes of Health, USA.
Yang Zhonghan, deputy general manager of Translab International Ltd., who used to work at the National Institutes of Health and co-founded the Taiwan Fucoidan Development Association with leaders from industry, government and medical research in recent years, and served as the secretary-general of the association for 10 years, said: “The application of Taiwanese small-molecule oligo fucoidan-related extraction technology in health food applications has always had purity problems such as precipitation and insolubility in water. There is still a gap between the 100% soluble purity used in actual scientific research.”
In response to the limitations of these early technologies, Translab has joined hands with Taiwan’s authorities on small molecule oligo fucoidan, combined with the resources of high-standard pharmaceutical companies to continue research and development and improve the process. It has upgraded Taiwan’s small molecule oligo fucoidan extraction technology to complete second-generation small molecules oligo fucoidan with high soluble purity. FOII® Fucoidan, the 2nd generation oligo fucoidan has been proven through testing to significantly enhance the bioactivity of Taiwanese small molecule oligo fucoidan. This technology was published in international journals this year and obtained a Taiwanese invention patent. It has now passed human clinical trials at a medical center and teaching hospital.
Development history of small molecule oligo fucoidan in Taiwan
Translab’s Human Clinical trial completed
The 2nd generation extraction technology was patented and listed in international medical journals
There are nearly 60 articles in international medical literature on Taiwanese fucoidan
Translab’s liquid fucoidan dosage form satisfaction 95%
Translab passed the human trial review by the medical center and teaching hospital
Translab obtained the SNQ National quality symbol, the purity and bioactivity have been greatly improved
Extraction technology upgraded to 2nd generation and technology transfer to Translab International Ltd.
2nd generation of Translab’s FOII oligo fucoidan developed
Tawian’s small molecule oligo fucoidan human clinical trial results published
1st generation extraction technology completes technology transfer
Development of small molecule oligo fucoidan extraction technology in Taiwan
There are nearly 2000 articles international medical literature related to fucoidan
Medical literature confirms the efficacy of fucoidan
Discover fucoidan from the brown alage can enhance the protection ability
Learn more: https://reurl.cc/oZXpEj
News website: https://news.tvbs.com.tw/life/1996539
